Clinical Trial Update: Phase 2 Study of ONC201 in Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 study of ONC201 in recurrent or metastatic neuroendocrine tumors has completed enrollment with results posted on 2024-11-26.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: Peter Anderson | Conditions: Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor | Phase 2 | Status: COMPLETED | Results posted: 2024-11-26